Regeneron Pharmaceuticals Accumulated Retained Earnings Deficit Trend

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

This module enables investors to look at Regeneron Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 311.7 M, Consolidated Income of 476.6 M or Cost of Revenue of 175.6 M, but also many exotic indicators such as Interest Coverage of 77.0381, Long Term Debt to Equity of 0.196 or Calculated Tax Rate of 10.7856. This module is a perfect complement to use when analyzing Regeneron Pharmaceuticals Valuation or Volatility. It can also complement various Regeneron Pharmaceuticals Technical models. Additionally take a look at analysis of Regeneron Pharmaceuticals Correlation with competitors.

Regeneron Pharmaceuticals Accumulated Retained Earnings Deficit Marginal Breakdown

Showing smoothed Accumulated Retained Earnings Deficit of Regeneron Pharmaceuticals with missing and latest data points interpolated. A component of [Equity] representing the cumulative amount of the entities undistributed earnings or deficit. May only be reported annually by certain companies; rather than quarterly.
Accumulated Retained Earnings Deficit10 Years Trend
Increasing
Slightly volatile
 Accumulated Retained Earnings Deficit 
      Timeline 

Regeneron Pharmaceuticals Regression Statistics

Arithmetic Mean 221,088,382
Geometric Mean 685,552,395
Coefficient Of Variation 495.20
Mean Deviation 915,733,280
Median 216,644,000
Standard Deviation 1,094,825,661
Range 3,015,545,000
R Value 0.83
R Squared 0.70
Significance 0.00074534
Slope 253,252,535

Regeneron Pharmaceuticals Accumulated Retained Earnings Deficit Over Time

2016  1,748,222,000 
2018  1,573,399,800 
2019  677,297,789 

Other Fundumenentals of Regeneron Pharmaceuticals

Search macroaxis.com